Senores Pharmaceuticals share price
NSE: SENORESBSE: 544319Pharmaceuticals & BiotechnologySmall Cap
Senores Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2024 · Issue price ₹391
Last close ₹1,324.30up ₹13.30 (1.01%)BSE ₹1,324.05
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,311.00.
28 Oct: open ₹1,315.00, high ₹1,341.00, low ₹1,309.70
52-week range of traded prices to 28 Oct 2026
₹706.00Low, 23 Mar 2026₹1,599.00High, 24 Aug 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,099 Cr841st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.53
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.34
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,86,87549.2% delivered
Results
Consolidated; ₹ crore.Senores Pharmaceuticals quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹180 Crup 2.87%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹30 Crdown 16.96%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 16.9%
Revenue by quarter
Net profit by quarter, a loss in red
The quarters either side of a change of basis do not compare. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹633 Cr, differs from its quarters added, ₹650 Cr.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 103 | 114 | 138 | 162 | 175 | 175 | 180 |
| Net profit | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| Net margin | 15.9% | 15.7% | 15.3% | 18.6% | 19.2% | 20.9% | 16.9% |
Consolidated. The 7 quarters from Dec 2024, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- Revenue
- ₹633 Cr
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹122 Crup 108.31%
- Net margin
- 19.2%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹633 Cr, differs from its quarters added, ₹650 Cr.
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 398 | 633 |
| Net profit | 58 | 122 |
| Net margin | 14.6% | 19.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2026: days before it are of the company before the change.Senores Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 65% of 241 trading days over the last year.
LowestHighest
Its median43.21Industry median27.98
Price to book
At or below today's level on 74% of 247 trading days over the last year.
LowestHighest
Its median5.10Industry median2.94
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +33.1% | +63.7% | −18.7% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
27 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 6 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 27 funds holding Senores Pharmaceuticals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 8
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
| Fund | |||
|---|---|---|---|
 HSBC Small Cap FundHSBC Mutual Fund | 4,94,440 | 0.37% | ₹68.5 Cr |
| HSBC Value FundHSBC Mutual Fund | 4,35,124 | 0.41% | ₹60.3 Cr |
 Mahindra Manulife Large & Mid Cap FundMahindra Manulife Mutual Fund | 4,29,600 | 2.16% | ₹59.5 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 4,03,526 | 0.66% | ₹55.9 Cr |
 TRUSTMF Small Cap FundTrust Mutual Fund | 3,46,668 | 1.24% | ₹48.0 Cr |
| HSBC Multi Cap FundHSBC Mutual Fund | 2,86,063 | 0.62% | ₹39.6 Cr |
| Bajaj Finserv Small Cap FundBajaj Finserv Mutual Fund | 2,19,483 | 1.10% | ₹30.4 Cr |
| Bajaj Finserv Multi Asset Allocation FundBajaj Finserv Mutual Fund | 1,13,314 | 0.82% | ₹15.7 Cr |
| HSBC India Export Opportunities FundHSBC Mutual Fund | 1,03,910 | 1.11% | ₹14.4 Cr |
| Mahindra Manulife Balanced Advantage FundMahindra Manulife Mutual Fund | 90,000 | 1.42% | ₹12.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Senores Pharmaceuticals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group2 purchases, 0 sales₹0.82 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.82 Cr2 pledges created · 1 pledge released · 2 pledge filings of unclear kind · 7 off-market moves
- Employees1 purchase, 0 sales₹0.02 CrNo saleNet₹0.02 Cr
- Others4 purchases, 0 sales₹0.07 CrNo saleNet₹0.07 Cr1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Senores Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Senores Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Bliss GVS PharmaBLISSGVS | 6,896 | 50.63 | 5.78 | +20.6% | +27.7% | 12.1% | 12.3% | 0.23% |
 Sanofi IndiaSANOFI | 6,891 | 21.28 | 8.34 | −8.9% | −10.7% | 40.3% | 54.0% | 4.11% |
 Morepen LaboratoriesMOREPENLAB | 6,881 | 36.50 | 4.98 | +30.2% | +91.2% | 14.6% | 14.3% | 0.16% |
 FDCFDC | 6,131 | 19.57 | 2.30 | +10.2% | +39.0% | 12.3% | 11.5% | 1.33% |
 Innova CaptabINNOVACAP | 6,007 | 38.43 | 5.55 | +34.5% | +20.4% | 15.3% | 15.0% | 0.19% |
 Sun Pharma Advanced Research CompanySPARC | 5,928 | 3.74 | 4.43 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
 IOL Chemicals and PharmaceuticalsIOLCP | 5,302 | 31.54 | 2.95 | +18.6% | +60.1% | 9.6% | 11.8% | 0.55% |
 Orchid PharmaORCHPHARMA | 5,180 | – | – | +26.2% | – | – | 0.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Senores Pharmaceuticals announcements
Oct 2026
23 Oct · Analysts
22 Oct · Analysts
22 Oct · Board meeting
16 Oct · Meeting
Sep 2026
Senores Pharmaceuticals share price by year
Each calendar year to 2025.Senores Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 822.20 | +44.6% | 827.65 | 444.30 |
| 2024 | 568.60 | – | 568.60 | 557.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 30 Dec 2024.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,255.00 | 1,318.00 | 1,248.90 | 1,311.00 | 1,293.27 | 2,04,236 | 49.4% |
| 26 Oct 2026 | 1,219.90 | 1,259.50 | 1,210.00 | 1,245.50 | 1,233.23 | 1,58,092 | 38.7% |
| 23 Oct 2026 | 1,210.80 | 1,220.60 | 1,168.10 | 1,215.30 | 1,199.55 | 1,65,744 | 43.3% |
| 22 Oct 2026 | 1,202.10 | 1,242.60 | 1,195.00 | 1,202.60 | 1,214.19 | 1,82,678 | 45.8% |
| 21 Oct 2026 | 1,253.60 | 1,255.20 | 1,196.00 | 1,224.10 | 1,219.83 | 3,03,198 | 54.5% |
| 19 Oct 2026 | 1,323.60 | 1,345.00 | 1,241.30 | 1,253.60 | 1,289.73 | 2,49,045 | 45.3% |
| 16 Oct 2026 | 1,258.80 | 1,324.40 | 1,253.60 | 1,318.40 | 1,294.14 | 2,86,388 | 43.4% |
| 15 Oct 2026 | 1,281.00 | 1,297.40 | 1,254.00 | 1,258.80 | 1,271.37 | 1,59,308 | 40.3% |
| 14 Oct 2026 | 1,321.00 | 1,325.30 | 1,271.00 | 1,281.50 | 1,291.53 | 1,45,695 | 60.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SENORES
- BSE code
- 544319
- ISIN
- INE0RB801010
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.senorespharma.com
- CIN
- L24290GJ2017PLC100263
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2017
- Registered office
- 1101 to 1103, South Tower ONE 42, 11th floor, Ambali Bopal Road, Opposite Jayantilal Park, Ahmedabad 380054, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments